JUPITER NEUROSCIENCES, INC. 8-K

What Happened

• Jupiter Neurosciences, Inc. (NASDAQ: JUNS) filed an 8-K on February 27, 2026 disclosing that Nasdaq notified the company it is out of compliance with two listing standards: the $1.00 minimum bid price (Rule 5550(a)(2)) and the $35 million market value of listed securities (MVLS) requirement (Rule 5550(b)(2)). Nasdaq’s review covered the 30-business-day periods ending February 25–26, 2026.
• The company has 180 calendar days (until August 25, 2026) to regain compliance on each deficiency. For the minimum bid price, compliance requires a closing bid of at least $1.00 for typically 10 consecutive business days (Nasdaq may require up to ~20). For MVLS, compliance requires MVLS at or above $35 million for at least 10 consecutive business days during the 180-day period.
• The notices do not affect trading today—JUNS will continue to trade on The Nasdaq Capital Market. The company said it will monitor the situation and may consider options such as a reverse stock split to cure the bid-price deficiency.

Key Details

• Nasdaq rules cited: Listing Rule 5550(a)(2) (minimum $1.00 bid) and 5550(b)(2) (MVLS $35M); procedural rules 5810(c)(3)(A) and 5810(c)(3)(C) give the 180-day cure periods.
• Deficiency measurement period for bid price: closing bids Jan 13–Feb 25, 2026 (30 consecutive business days); MVLS deficiency noted for the 30 business days ended Feb 26, 2026.
• Cure deadline for both deficiencies: August 25, 2026; failure to cure may lead to delisting proceedings, subject to appeal to a Nasdaq hearings panel.
• Regulation FD disclosure: the company may use its website (https://jupiterneurosciences.com) and social channels (X: @jupiterneuro; Instagram: @Nugevia) for material communications.

Why It Matters

• These notices signal a risk to JUNS’s continued Nasdaq listing if the company cannot restore the share price or market value within the stated cure periods. A delisting could reduce liquidity and investor visibility.
• The company has options (including corporate actions like a reverse stock split) to regain compliance, but there is no assurance of success. Investors should monitor JUNS trading, corporate announcements, SEC filings, and the company’s stated social media channels for updates.